Actively Recruiting
PIK3CA Mutational Status Assessment
Led by European Institute of Oncology · Updated on 2026-03-24
100
Participants Needed
1
Research Sites
320 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
Evaluation of PIK3CA mutational status: a route towards a tailored diagnostic approach.
CONDITIONS
Official Title
PIK3CA Mutational Status Assessment
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Histologically and/or cytologically confirmed diagnosis of ER+ and/or PgR+ breast cancer by local laboratory
- HER2-negative breast cancer defined as negative in situ hybridization test or IHC status of 0, 1+ or 2+ with negative in situ hybridization if IHC is 2+
- Advanced or metastatic breast cancer prior to treatment
- Signed and dated written informed consent by patient and investigator
- Accessibility for follow-up
You will not qualify if you...
- Patients already treated with chemotherapy, hormone therapy, or other treatments
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
European Institute of Oncology
Milan, MI, Italy, 20141
Actively Recruiting
Research Team
N
Nicola Fusco, MD
CONTACT
F
francesca lombardi, biologist
CONTACT
How is the study designed?
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
0
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here